Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 Diabetes
Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 Diabetes
study hypothesis to examine the acute effects on glycaemia and islet hormone secretion of
 increased levels of endogenous GLP-1 and GIP on islet cell function in men with type 2
 diabetes. To this purpose, a standardized mixed meal test will be ingested with or without
 concomitant administration of sitagliptin (100mg).
In men subjects with type 2 diabetes treated with diet and exercise with or without metformin
 treatment as an antidiabetic agent, a standardized mixed meal test will be served with or
 without administration of sitagliptin (100mg).
Inclusion Criteria:

 -  Caucasian men with type 2 diabetes diagnosed according to ICD10

 -  Ongoing treatment with life style adjustment or life style adjustment together with
 metformin as oral antidiabetic. Metformin therapy should not exceed 2 grams daily

 -  Age 20-75 years

 -  HbA1c ≤80 mmol/mol

 -  BMI: 20-40 kg/m2

 Exclusion Criteria:

 -  Liver disease or ALAT three times above upper reference range

 -  Diabetic nephropathy (GFR < 50 mL/min/1.73 m2 or albuminuria)

 -  Proliferative diabetic retinopathy

 -  Treatment with any glucose-lowering medication except metformin

 -  Previous myocardial infarction, coronary heart disease or insatiable angina pectoris
 in the last 6 months.

 -  Previous surgery on the gastrointestinal tract

 -  Larger surgical intervention during the last 12 weeks

 -  Treatment with oral steroids or thiazide diuretics

 -  Treatment with digoxin

 -  Smokers

 -  Participation in another study the last 4 weeks

 -  Paracetamol intolerance